Crystalline Inorganic Anion Exchanger 188Re Generator

结晶无机阴离子交换器188Re发生器

• 批准号: 6944263
• 负责人: ALAN J CISAR
• 金额: $ 46.3万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-16 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6944263
• 关键词: anions; beta radiation; bioengineering /biomedical engineering; biomedical equipment development; chemical kinetics; chemical stability; chemical structure function; chemical synthesis; crystallization; heavy metals; intermolecular interaction; ion exchange chromatography; tungsten

DESCRIPTION (provided by applicant): A high-energy beta (beta-) emission and short half life (16.9 hr) makes 188Re an excellent isotope for radiotherapeutic applications. The similarity in the chemical behavior of Re and Tc means that imaging [protocols developed for 99mTc can be directly converted to therapeutic protocols for 188Re. Unfortunately the short half-life that makes Re attractive as a therapeutic agent makes it impossible to supply from a central source. Current generators are not adequate for the reliable delivery of pure 188Re at the end user site. The aim of this project is to develop a superior generator system for 188Re with an increased operating life to reduce the cost and improve the availability of the radioisotope to end-users. Crystalline inorganic compounds under consideration are layered aluminum mixed hydroxides, which can be synthesized as anion exchangers. The ideal compound strongly retains divalent tungstate (WO4 =) but not monovalent perrhenate (ReO4-). After testing a range of compositions for both magnesium and lithium aluminates compositions were entitled with high tungstate retentions (Kd >1.8 . 10[6] for Mg and >8 . 10[4] for Li). Based on equilibrium tests, these compositions had WO4=/ReO4 - separation factors of 18,000 and 500 respectively. The compositions were pelletized (<300 mu m) and used to produce small generators, which were tested and found to reliably deliver 188Re completely free of 188W, demonstrating separation factors greater than those seen in the equilibration tests. Phase II of this project will include improved pelletization and exchange kinetics for the ion exchangers and will culminate in the fabrication and testing of full size generators based on this technology. The ultimate goal of this project is a commercially viable 188Re generator for use in end use facilities such as hospitals, radiopharmacies, and regional radiopharmacies serving multiple hospitals. This will improve the availability of 188Re for use as the active component for radioimmunotherapy (RIT) and similar techniques.

描述（由申请人提供）： 高能β（β-）发射和短期寿命（16.9小时）使188RE成为放射治疗应用的绝佳同位素。 RE和TC的化学行为的相似性意味着成像[为99MTC开发的方案可以直接转换为188RE的治疗方案。不幸的是，短期的半衰期使Re作为治疗剂的吸引力使得无法从中央来源提供。当前的发电机不足以在最终用户站点在最终用户站点上可靠地交付纯188RE。该项目的目的是为188RE开发出色的发电机系统，并增加了运营寿命，以降低成本并提高放射性同位素的最终用户的可用性。所考虑的晶体无机化合物是分层的铝混合氢氧化物，可以合成为阴离子交换剂。理想的化合物强烈保留二价钨（WO4 =），但不能保留单价perrhenate（reo4-）。在测试了一系列镁和锂铝成分的组合物之后，具有高钨的保留率（Kd>1.8。10[6]，用于mg，>8。10[4]对于Li）。根据平衡测试，这些组合物的wo4 =/reo4-分离因子分别为18,000和500。将组合物颗粒化（<300 mu m），用于产生小发电机，该发电机经过测试并发现可靠地递送188re完全没有188W，显示出比平衡测试中看到的分离因子大。该项目的第二阶段将包括改善离子交换器的颗粒化和交换动力学，并将在基于该技术的全尺寸生成器制造和测试中达到高潮。该项目的最终目标是一种商业上可行的188RE发电机，可用于最终使用设施，例如医院，放射性药物和为多家医院提供服务的区域放射线药物。这将提高188RE的可用性，以作为放射免疫疗法（RIT）和类似技术的主动组件。